PMID- 23657965
OWN - NLM
STAT- MEDLINE
DCOM- 20131126
LR  - 20211021
IS  - 1423-0380 (Electronic)
IS  - 1010-4283 (Linking)
VI  - 34
IP  - 5
DP  - 2013 Oct
TI  - Monocyte chemotactic protein-1 and CC chemokine receptor 2 polymorphisms and 
      prognosis of renal cell carcinoma.
PG  - 2741-6
LID - 10.1007/s13277-013-0827-7 [doi]
AB  - Monocyte chemoattractant protein-1 (MCP-1) and its receptor CC chemokine receptor 
      2 (CCR2) play a major role in inflammation and proliferation of cancers. We 
      investigated a possible association between polymorphisms in MCP-1 and CCR2 genes 
      (MCP-1 -2518A/G and CCR2 190G/A or V64I) and the risk as well as prognosis of 
      renal cell carcinoma (RCC). Genotypes were determined by polymerase chain 
      reaction-restriction fragment length polymorphism in 416 RCC cases and 458 
      age-matched healthy controls. Frequency of MCP-1 2518GG genotype for cases and 
      controls was 0.384 and 0.286, respectively; individuals carrying the GG genotype 
      had a 1.89-fold increased risk of RCC than those with AA genotype (95 % 
      confidence interval [CI] 1.24-2.81, p = 0.002; data were adjusted for age and 
      sex). Frequency of CCR2 190AA (64I/64I) genotype for cases and controls was 0.175 
      and 0.076, respectively; subjects having AA genotype had a 2.68-fold increased 
      risk of RCC compared to those with the wild-type GG genotype (95 %CI 1.71-4.17, p 
      = 4.3 x 10(-6); data were adjusted for age and sex). When analyzing the survival 
      rate of RCC, patients with MCP-1 -2518GG genotype revealed significantly shorter 
      survival time compared to cases with MCP-1 -2518AA and AG genotypes (p = 0.003). 
      Similarly, RCC cases carrying CCR2 190AA genotype showed significantly shorter 
      survival rate than patients with GG or GA genotypes (p < 0.001). These data 
      suggested that MCP-1 -2518A/G and CCR2 190G/A polymorphisms are new risk factors 
      for RCC and could be used as prognostic markers for this malignancy.
FAU - Liu, Guan-Xian
AU  - Liu GX
AD  - Department of Nephrology, Huizhou Municipal Central Hospital, 41 E Ling Bei Road, 
      Huizhou, Guangdong, 516001, China, guanxian_liu@126.com.
FAU - Zhang, Xin
AU  - Zhang X
FAU - Li, Su
AU  - Li S
FAU - Koiiche, Richard D
AU  - Koiiche RD
FAU - Sindsceii, Jerry H
AU  - Sindsceii JH
FAU - Song, Haihan
AU  - Song H
LA  - eng
PT  - Journal Article
DEP - 20130509
PL  - Netherlands
TA  - Tumour Biol
JT  - Tumour biology : the journal of the International Society for Oncodevelopmental 
      Biology and Medicine
JID - 8409922
RN  - 0 (CCL2 protein, human)
RN  - 0 (CCR2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Receptors, CCR2)
SB  - IM
MH  - Aged
MH  - Amino Acid Substitution
MH  - Carcinoma, Renal Cell/*genetics/mortality/secondary
MH  - Case-Control Studies
MH  - Chemokine CCL2/*genetics
MH  - Female
MH  - Gene Frequency
MH  - Genetic Association Studies
MH  - Genetic Predisposition to Disease
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Kidney Neoplasms/*genetics/mortality/pathology
MH  - Male
MH  - Middle Aged
MH  - *Polymorphism, Single Nucleotide
MH  - Prognosis
MH  - Receptors, CCR2/*genetics
EDAT- 2013/05/10 06:00
MHDA- 2013/12/16 06:00
CRDT- 2013/05/10 06:00
PHST- 2013/03/10 00:00 [received]
PHST- 2013/04/29 00:00 [accepted]
PHST- 2013/05/10 06:00 [entrez]
PHST- 2013/05/10 06:00 [pubmed]
PHST- 2013/12/16 06:00 [medline]
AID - 10.1007/s13277-013-0827-7 [doi]
PST - ppublish
SO  - Tumour Biol. 2013 Oct;34(5):2741-6. doi: 10.1007/s13277-013-0827-7. Epub 2013 May 
      9.